Edrecolomab

From Wikipedia, the free encyclopedia

You have new messages (last change).
This article is uncategorized.
Please help improve this article by adding it to one or more categories, so it may be associated with related articles (how?). Please remove this tag after categorizing. This article has been tagged since November 2006.

Edrecolomab (MAb17-1A) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary studies had shown promise of a possible use in patients with colorectal carcinoma. However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents [1]. It is important to mention that edrecolomab was well tolerated and as such research has now concentrated on whether it can be of any use in other forms of cancer.

[edit] References

  1. ^ Punt CJ et al, Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. The Lancet, Volume 360, Issue 9334, Pages 671-677 [1]
Retrieved from "http://en.wikipedia.org../../../e/d/r/Edrecolomab.html"